| Literature DB >> 29212177 |
Chunhui Bao1, Peng Liu2, Yin Shi3, Luyi Wu1, Xiaoming Jin4, Xiaoqing Zeng5, Jianye Zhang6, Di Wang1, Huirong Liu3, Huangan Wu1.
Abstract
Increasing evidence indicates that abnormal pain processing is present in the central nervous system of patients with Crohn's disease (CD). The purposes of this study were to assess changes in gray matter (GM) volumes in CD patients in remission and to correlate structural changes in the brain with abdominal pain. We used a 3.0 T magnetic resonance scanner to examine the GM structures in 21 CD patients with abdominal pain, 26 CD patients without abdominal pain, and 30 healthy control subjects (HCs). Voxel-based morphometric analyses were used to assess the brain GM volumes. Patients with abdominal pain exhibited higher CD activity index and lower inflammatory bowel disease questionnaire scores than those of the patients without abdominal pain. Compare to HCs and to patients without abdominal pain, patients with abdominal pain exhibited lower GM volumes in the insula and anterior cingulate cortex (ACC); whereas compare to HCs and to patients with abdominal pain, the patients without abdominal pain exhibited higher GM volumes in the hippocampal and parahippocampal cortex. The GM volumes in the insula and ACC were significantly negatively correlated with daily pain scores. These results suggest that differences exist in the brain GM volume between CD patients in remission with and without abdominal pain. The negative correlation between the GM volumes in the insula and ACC and the presence and severity of abdominal pain in CD suggests these structures are closely related to visceral pain processing.Entities:
Keywords: Crohn’s disease; brain; gray matter; magnetic resonance imaging; pain
Year: 2017 PMID: 29212177 PMCID: PMC5706823 DOI: 10.18632/oncotarget.21161
Source DB: PubMed Journal: Oncotarget ISSN: 1949-2553
Clinical demographics of the CD with pain, pain-free CD, and HC groups
| CD with Pain ( | Pain-free CD ( | HC ( | |||
|---|---|---|---|---|---|
| Gender (male/female) | 12/9 | 20/6 | 20/10 | 0.352 | |
| Age (years) | 30.86 ± 6.99 | 29.77 ± 7.23 | 30.47 ± 5.93 | 0.850 | |
| Height (cm) | 169.33 ± 8.71 | 170.69 ± 5.96 | 169.60 ± 7.68 | 0.794 | |
| Weight (kg) | 55.88 ± 9.66 | 57.62 ± 9.37 | 59.10 ± 6.47 | 0.410 | |
| HADS-A | 6.52 ± 3.75** | 5.27 ± 2.66* | 3.40 ± 2.01 | 0.001 | |
| HADS-D | 5.90 ± 3.99** | 3.65 ± 2.87 | 3.00 ± 1.72 | 0.002 | |
| Disease duration (months) | 88.29 ± 52.76 | 68.77 ± 45.04 | — | 0.178 | |
| CDAI | 93.86 ± 36.00### | 44.52 ± 30.74 | — | 0.000 | |
| IBDQ | 162.95 ± 29.74## | 187.77 ± 18.76 | — | 0.003 | |
| PLT | 229.81 ± 33.00 | 209.00 ± 49.63 | — | 0.106 | |
| ESR | 12.37 ± 5.10 | 9.85 ± 5.70 | — | 0.123 | |
| CRP | 5.46 ± 2.35## | 2.92 ± 2.72 | — | 0.002 | |
| CDEIS | 1.24 ± 0.76 | 0.89 ± 0.50 | — | 0.068 | |
| Montreal classificationΔ | |||||
| Age at diagnosis | A1 | 0 | 4 | — | 0.074 |
| A2 | 20 | 22 | — | ||
| A3 | 1 | 0 | — | ||
| Location | L1 | 3 | 7 | — | 0.606 |
| L2 | 4 | 5 | — | ||
| L3 | 14 | 14 | — | ||
| L4 | 0 | 0 | — | ||
| Behavior | B1 | 7 | 9 | — | 0.385 |
| B2 | 1 | 2 | — | ||
| B3 | 6 | 7 | — | ||
| B1P | 0 | 4 | — | ||
| B2P | 1 | 0 | — | ||
| B3P | 6 | 4 | — | ||
| Concomitant medication | 15 | 15 | — | ||
| 5-Aminosalicylate | 9 | 7 | — | 0.240 | |
| Azathioprine | 3 | 7 | — | ||
| 5-Aminosalicylate & azathioprine | 3 | 1 | — | ||
*P < 0.05 and **P < 0.01 compared with the HC group; ##P < 0.01 and ###P < 0.001, compared with the pain-free group; Δ Montreal classification: A1, below 16 years; A2, between 17-40 years; A3, above 40 years; L1, ileal; L2, colonic; L3, ileocolonic; L4, isolated upper disease; B1, non-stricturing, non-penetrating; B2, structuring; B3, penetrating; P, perianal disease modifier. CD, Crohn’s disease; CDAI, Crohn’s Disease Activity Index; CDEIS, Crohn’s disease endoscopic index of severity; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; HADS-A, Hospital Anxiety and Depression Scale anxiety score; HADS-D, Hospital Anxiety and Depression Scale depression score; HCs, healthy controls; IBDQ, Inflammatory Bowel Disease Questionnaire; PLT, platelet. Values are presented as the mean values (standard deviations).
Brain regions with significant differences in GM volume among the CD with pain, pain-free CD, and HC groups
| Regions | Hem | BA | MNI | Voxels | |||
|---|---|---|---|---|---|---|---|
| X | Y | Z | |||||
| ACC | R | 32 | 3 | 51 | 15 | 7.98 | 151 |
| Insula | L | 47 | 39 | 21 | 3 | 9.61 | 137 |
| HIPP/paraHIPP | L | 28 | -18 | –6 | -24 | 10.09 | 178 |
| Putamen | L | 11 | -24 | 15 | -3 | 17.56 | 417 |
The results were based on the total GM volume, age, gender, weight, anxiety and depression as covariates. The statistical threshold was set at P < 0.05, and the false discovery rate was corrected for multiple comparisons. ACC, anterior cingulate cortex; CD, Crohn’s disease; HC, healthy controls; HIPP/paraHIPP, hippocampal and parahippocampal cortex; L, left hemisphere; R, right hemisphere.
Figure 1Significant differences in GM volumes in patients with CD-related pain, CD without pain, and HC groups with total GM volume, age, gender, weight, anxiety and depression as covariates
(A) GM volumes of the putamen, HIPP/paraHIPP, insula and ACC differed significantly among the 3 groups. (B) Post-hoc analysis showed that the GM volumes of the insula and ACC in the CD with pain group were lower than the GM volumes in the remaining two groups. The GM volumes of the HIPP/paraHIPP in the pain-free group were higher than the GM volumes in the remaining two groups. The GM volumes of the putamen in the HC group were lower than the GM volumes in the remaining two groups, but the CD with pain and pain-free CD groups were not significantly different. (C) Correlation analysis between the GM volumes of the ROIs in the CD with pain group and the pain scores. ACC, anterior cingulate cortex; CD, Crohn’s disease; HC, healthy controls; HIPP/paraHIPP, hippocampal and parahippocampal cortex; L, left hemisphere; r, correlation coefficient; ROI, region of interest; VAS, visual analogue scale; *P < 0.05, **P < 0.01, ***P < 0.005.
The post-hoc analysis of the GM volume in the brain regions with significant differences among the CD with pain, pain-free CD, and HC groups
| Regions | CD with pain ( | Pain-free CD ( | HC ( | Pain vs. pain-free | Pain vs. HC | Pain-free vs. HC | |||
|---|---|---|---|---|---|---|---|---|---|
| Effect size | Effect size | Effect size | |||||||
| ACC_R | 0.56 ± 0.15 | 0.67 ± 0.19 | 0.70 ± 0.14 | 0.64 | 0.02 | 0.96 | 0.002 | 0.18 | 0.432 |
| Insula_L | 0.75 ± 0.09 | 0.83 ± 0.10 | 0.85 ± 0.10 | 0.84 | 0.009 | 1.05 | 0.001 | 0.20 | 0.417 |
| HIPP/paraHIPP_L | 1.04 ± 0.10 | 1.10 ± 0.10 | 1.02 ± 0.08 | 0.70 | 0.018 | 0.22 | 0.295 | 1.06 | 0.000 |
| Putamen_L | 0.98 ± 0.15 | 1.00 ± 0.11 | 0.87± 0.12 | 0.15 | 0.619 | 0.81 | 0.003 | 1.13 | 0.000 |
Data are present as mean ± SD. ACC, anterior cingulate cortex; CD, Crohn’s disease; HC, healthy controls; HIPP/paraHIPP, hippocampal and parahippocampal cortex; L, left hemisphere; R, right hemisphere.
Whole-brain correlation analysis between the GM volumes and daily pain scores in CD patients with abdominal pain
| Regions | Hem | BA | MNI | Voxels | |||
|---|---|---|---|---|---|---|---|
| X | Y | Z | |||||
| ACC | R | 11 | 3 | 36 | –3 | –4.37 | 127 |
| Insula | R | 47 | 41 | 24 | 0 | –4.86 | 134 |
| Insula | L | 47 | –38 | 21 | 0 | –5.56 | 120 |
| OFC | L | 11 | –3 | 58 | –9 | –5.33 | 123 |
The results employed age, gender, weight, anxiety and depression as covariates. The statistical threshold was set at P < 0.005 (uncorrected) and cluster P < 0.05 (false discovery rate corrected). ACC, anterior cingulated cortex; BA, Brodmann area; Hem, hemisphere; L, left; OFC, orbitofrontal cortex; R, right.
Figure 2Brain regions with significant correlation between the GM volumes and daily pain scores in CD patients with abdominal pain using whole-brain correlation analysis
The daily pain scores correlated negatively with the GM volumes of the right ACC, left OFC, and bilateral insula.